Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines have been placed on mute to prevent any background noise. After the ...

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...

Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access.

Stratos Wealth Partners LTD. purchased a new stake in DexCom, Inc. (NASDAQ:DXCM – Free Report) in the fourth quarter, HoldingsChannel.com reports. The fund purchased 2,583 shares of the medical device ...

A U.K. court has ruled against Abbott in a trademark infringement case the company had brought over the design of a rival ...

DexCom Inc (DXCM) reports strong international growth and expanding customer base, while facing margin pressures and US ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, ...

Dexcom (Nadsaq:DXCM) shares fell after hours today on fourth-quarter results that came in mixed compared to the consensus forecast.